- Target disease: Visceral leishmaniasis (VL)
- Main Partners (since project start): Celgene Global Health, USA; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene & Tropical Medicine, UK; Sandexis, UK; WuXi AppTech, China.
- Project start: 2015
- Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International.
A novel series of heterocyclic compounds for VL has been optimized by Celgene in collaboration with London School of Hygiene & Tropical Medicine and Advinus, and with advice from DNDi.
DNDi’s collaboration with Celgene Global Health continues to explore the potential of this series to deliver a pre-clinical candidate. Compounds with much improved physical properties, including improved aqueous solubility, were identified in 2017.
Last update: August 2018